| UniProt ID | NAGK_HUMAN | |
|---|---|---|
| UniProt AC | Q9UJ70 | |
| Protein Name | N-acetyl-D-glucosamine kinase | |
| Gene Name | NAGK | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 344 | |
| Subcellular Localization | ||
| Protein Description | Converts endogenous N-acetylglucosamine (GlcNAc), a major component of complex carbohydrates, from lysosomal degradation or nutritional sources into GlcNAc 6-phosphate. Involved in the N-glycolylneuraminic acid (Neu5Gc) degradation pathway: although human is not able to catalyze formation of Neu5Gc due to the inactive CMAHP enzyme, Neu5Gc is present in food and must be degraded. Also has ManNAc kinase activity.. | |
| Protein Sequence | MAAIYGGVEGGGTRSEVLLVSEDGKILAEADGLSTNHWLIGTDKCVERINEMVNRAKRKAGVDPLVPLRSLGLSLSGGDQEDAGRILIEELRDRFPYLSESYLITTDAAGSIATATPDGGVVLISGTGSNCRLINPDGSESGCGGWGHMMGDEGSAYWIAHQAVKIVFDSIDNLEAAPHDIGYVKQAMFHYFQVPDRLGILTHLYRDFDKCRFAGFCRKIAEGAQQGDPLSRYIFRKAGEMLGRHIVAVLPEIDPVLFQGKIGLPILCVGSVWKSWELLKEGFLLALTQGREIQAQNFFSSFTLMKLRHSSALGGASLGARHIGHLLPMDYSANAIAFYSYTFS | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 2 | Acetylation | ------MAAIYGGVE ------CCCEECCCC | 11.54 | 22223895 | |
| 5 (in isoform 2) | Phosphorylation | - | 11.78 | 27251275 | |
| 5 | Phosphorylation | ---MAAIYGGVEGGG ---CCCEECCCCCCC | 11.78 | 25693802 | |
| 7 (in isoform 2) | Phosphorylation | - | 9.42 | 27251275 | |
| 13 | Phosphorylation | GGVEGGGTRSEVLLV CCCCCCCCCEEEEEE | 34.01 | 25693802 | |
| 15 | Phosphorylation | VEGGGTRSEVLLVSE CCCCCCCEEEEEECC | 31.71 | 25693802 | |
| 40 (in isoform 2) | Phosphorylation | - | 4.75 | 22210691 | |
| 41 (in isoform 2) | Phosphorylation | - | 26.20 | 22210691 | |
| 44 | Ubiquitination | HWLIGTDKCVERINE CEEECCHHHHHHHHH | 39.76 | - | |
| 44 | Acetylation | HWLIGTDKCVERINE CEEECCHHHHHHHHH | 39.76 | 25953088 | |
| 51 (in isoform 2) | Phosphorylation | - | 41.98 | 22210691 | |
| 59 | Ubiquitination | MVNRAKRKAGVDPLV HHHHHHHHCCCCCCC | 49.11 | - | |
| 70 | Phosphorylation | DPLVPLRSLGLSLSG CCCCCHHHCCCCCCC | 34.18 | 23927012 | |
| 74 | Phosphorylation | PLRSLGLSLSGGDQE CHHHCCCCCCCCCHH | 20.77 | 29255136 | |
| 76 | Phosphorylation | RSLGLSLSGGDQEDA HHCCCCCCCCCHHHH | 37.04 | 19664994 | |
| 90 | Ubiquitination | AGRILIEELRDRFPY HHHHHHHHHHHHCCC | 41.95 | - | |
| 105 | Ubiquitination | LSESYLITTDAAGSI CCCCEEEEECCCCCC | 18.94 | - | |
| 106 | Phosphorylation | SESYLITTDAAGSIA CCCEEEEECCCCCCE | 19.35 | - | |
| 116 | Phosphorylation | AGSIATATPDGGVVL CCCCEEECCCCCEEE | 19.98 | - | |
| 120 | Phosphorylation | ATATPDGGVVLISGT EEECCCCCEEEEECC | 17.46 | 24719451 | |
| 122 | Phosphorylation | ATPDGGVVLISGTGS ECCCCCEEEEECCCC | 4.43 | 19664994 | |
| 205 | Phosphorylation | LGILTHLYRDFDKCR HCHHHHHHHCHHHCC | 10.67 | 14702039 | |
| 219 | Ubiquitination | RFAGFCRKIAEGAQQ CHHHHHHHHHHHHHC | 47.66 | - | |
| 219 | Malonylation | RFAGFCRKIAEGAQQ CHHHHHHHHHHHHHC | 47.66 | 26320211 | |
| 237 | Ubiquitination | LSRYIFRKAGEMLGR HHHHHHHHHHHHHHC | 50.42 | - | |
| 251 | Phosphorylation | RHIVAVLPEIDPVLF CHHEEEECCCCHHHC | 29.87 | 12112843 | |
| 265 | Ubiquitination | FQGKIGLPILCVGSV CCCCCCCCEEEEHHH | 16.58 | - | |
| 271 | Phosphorylation | LPILCVGSVWKSWEL CCEEEEHHHHHHHHH | 12.38 | 28348404 | |
| 283 | Ubiquitination | WELLKEGFLLALTQG HHHHHHCHHHHHHCC | 5.46 | - | |
| 317 | Phosphorylation | SSALGGASLGARHIG CHHCCCCCCCHHHHH | 30.52 | 27251275 |
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of NAGK_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of NAGK_HUMAN !! | ||||||
| Kegg Disease | |
|---|---|
| There are no disease associations of PTM sites. | |
| OMIM Disease | |
| There are no disease associations of PTM sites. | |
| Kegg Drug | |
| There are no disease associations of PTM sites. | |
| DrugBank | |
| DB00141 | N-Acetyl-D-glucosamine |
loading...
| Phosphorylation | |
| Reference | PubMed |
| "Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76, AND MASSSPECTROMETRY. | |
| "A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76, AND MASSSPECTROMETRY. | |
| "Identification of the phosphotyrosine proteome from thrombinactivated platelets."; Maguire P.B., Wynne K.J., Harney D.F., O'Donoghue N.M., Stephens G.,Fitzgerald D.J.; Proteomics 2:642-648(2002). Cited for: PHOSPHORYLATION AT TYR-205. | |